Introduction: Psoriasis is chronic immune-mediated disease with a focus on the skin. This condition, which relapses and remitsovera patient's lifetime, affects about 1%-6% of the Indian population. Topical corticosteroids, vitamin D analogues, and retinoids are recommended by the American Academy of Dermatology and the National Psoriasis Foundation as first-line treatments for people with mild to moderate localized plaque psoriasis. Recent studies show role of vitamin D in many immune mediated skin diseases like psoriasis and oral vitamin D remain safe, widely available and inexpensive treatment. Vitamin D3 have also some effects in metabolic syndrome. Aim: Aim of the study is to see the efficacy and safety of oral vitamin D3 in addition to topical clobetasol propionate 0.05% cream in patients of chronic plaque psoriasis. Methodology: 64 patients from Department of Dermatology, Venereology and Leprosy, sir T hospital Bhavnagar of chronic plaque psoriasis were randomly divided in two groups. Both the groups were followed up for 10 weeks and evaluated with gross photographs, PASI score and global improvement score. Results: After 10 weeks improvement in PASI in Group A was 5.17±3.14 and in Group B 6.88±4.06. But while comparing both means using Mann Whitney test, P value was 0.029 which was considered significant. While GIS between group A and Group B was not significant with p value =0.264. Conclusion: Oral vitamin D can be safe, effective, and cheap therapeutic modality as supplement with topical steroids to psoriasis patients. Unlike most systemic drugs currently used in psoriasis, the adverse effects of which are significant, and many of them are costly.